Search results
...Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1...
Morningstar· 3 days agoPAS-004 is being evaluated in a Phase 1 multicenter open label clinical trial (NCT06299839) in patients with MAPK pathway driven advanced solid tumors with a documented RAS, NF1 or RAF mutation ...
Final first responder convicted in Elijah McClain's death to be sentenced
WSB Radio· 1 day agoFormer paramedic Jeremy Cooper is set to be sentenced Friday after being found guilty of criminally...
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday? - Immutep (NASDAQ:IMMP)
Benzinga· 3 days agoImmutep releases preliminary results from TACTI-003 trial showing promising outcomes for first-line...
NHS trials first personal skin cancer jab that can halve risk of death
The Telegraph via Yahoo News· 2 days agoIt is also undergoing early testing on other cancers. Around 70 Britons are set to take part in a...
A Collier deputy testified about his on-the-job fentanyl overdose. Did it really happen?
Naples Daily News via Yahoo News· 2 days ago“The initial concern leads to true physiologic fight-or-flight response,” he said. Last year,...
H.C. Wainwright Cuts HOOKIPA Pharma Shares target on Narrower HB-200 Target Population By...
Investing.com· 1 day agoOn Thursday, H.C. Wainwright adjusted its price target for HOOKIPA Pharma Inc. (NASDAQ:HOOK) shares,...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 6 days agoAnthos Therapeutics, Inc. (Anthos), is a clinical-stage company developing innovative therapies for cardiovascular diseases, founded by Blackstone Life Sciences (BXLS), today announced the appointment ...
Oruka Therapeutics Expands Leadership Team, Naming Joana Goncalves, MBChB, as Chief Medical Officer
Morningstar· 3 days agoOruka Therapeutics, Inc. (“Oruka”), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including ...
Big Pharma's Blockbuster Creation Continues to Disappoint
Mercola· 4 days ago"We are taking this very seriously," Carl Dieffenbach, head of the Division of AIDS at the National Institute of Allergy and Infectious Diseases (NIAID), told Science.3 Although all HIV mRNA ...
Updates in Managing Elderly Patients With Type 2 Diabetes
Medscape· 4 days agoThe management of patients over the age of 75 years with diabetes is discussed in a crucial chapter...